Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$28.71 USD
-0.77 (-2.61%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $28.72 +0.01 (0.03%) 7:36 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Ultragenyx Pharmaceutical Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
RARE 28.71 -0.77(-2.61%)
Will RARE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Other News for RARE
Pocket Pivot appears for RARE after 1.66% move
20 Day Moving Average Resistance appears for RARE after 4.32% move
Tracking Baker Brothers Portfolio - Q2 2025 Update
Is RARE ready to move lower? Fell Below 20 Day Moving Average shows up after dropping 2.95%
Non-ADX 1,2,3,4 Bullish appears for RARE after 0.19% move